Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;5(4):484-90.
doi: 10.1097/JTO.0b013e3181ccb27b.

Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer

Alberto A Chiappori  1 , Zhong Zheng, Tingan Chen, Bhupendra Rawal, Michael J Schell, Brian P Mullaney, Gerold Bepler
Affiliations

Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer

Alberto A Chiappori et al. J Thorac Oncol. 2010 Apr.

Abstract

Introduction: One-size-fits-all chemotherapy does not improve survival in patients with small cell lung cancer (SCLC). Excision repair cross-complementing group 1 (ERCC1), ribonucleotide reductase 1 (RRM1), thymidylate synthase (TS), and topoisomerase 2alpha (Topo2alpha) expression levels are predictive of chemotherapeutic efficacy in some malignancies. Our aim was to determine the expression levels of these proteins to assess their potential clinical utility in SCLC.

Methods: We used an immunofluorescence-based automated quantitative technique to score RRM1, ERCC1, TS, and Topo2alpha levels in tumor specimens from 100 patients with SCLC and immunohistochemistry to semiquantitatively score levels of TS, 5-phosphoribosyl-glycinamide formyl-transferase, and folyl-polyglutamate synthase expression. Confocal microscopy was used for subcellular localization in SCLC cells.

Results: RRM1, ERCC1, and Topo2alpha staining was predominantly nuclear and TS mainly cytoplasmic. Using immunohistochemistry, we found that TS (antibody 106) and TS (antibody 4H4) scores were strongly correlated (r = 0.82, p < 0.0001). By automated quantitative technique, RRM1 and Topo2alpha levels were highly correlated (r = 0.56, p < 0.0001). ERCC1 and TS levels had a narrow and low range of expression. There was no correlation between any of these biomarkers and patients' age or sex.

Conclusion: Considering this clinical evidence, expression levels of RRM1 and Topo2alpha may have utility for chemotherapy customization. Clinical validation of their predictive power is desirable in a prospective clinical trial.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Confocal microscopy images of the 4 biomarkers in the H69 small cell lung cancer cell line. DAPI, 4’,6-diamidino-2-phenylindole; RRM1, ribonucleotide reductase 1; ERCC1, excision repair cross complementing group 1; TS, thymidylate synthase; Topo2α, topoisomerase 2α.
Figure 2
Figure 2
Multidimensional scaling plot of IHC and AQUA scores.
See this image and copyright information in PMC

References

    1. Janne PA, Freidlin B, Saxman S, et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer. 2002;95:1528–1538. - PubMed
    1. Simon GR, Wagner H. Small cell lung cancer. Chest. 2003;123:259S–271S. - PubMed
    1. Davies AM, Lara PN, Lau DH, Gandara DR. Treatment of extensive small cell lung cancer. Hematol Oncol Clin North Am. 2004;18:373–385. - PubMed
    1. Ettinger DS. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol. 2001;28:27–29. - PubMed
    1. Ettinger DS. Single-agent paclitaxel in the treatment of small cell lung cancer. Semin Oncol. 1996;23:16–17. - PubMed

Publication types

MeSH terms